Innovative therapeutics

Investors

Financial Statements

NASDAQBMRN
All numbers in thousands USD
Period Ending
Dec 31, 2016
Dec 31, 2015
Dec 31, 2014
Dec 31, 2013
Net Income
(630,210)
(171,799)
(133,969)
(176,353)
Operating Activities, Cash Flows Provided By or Used In
Depreciation
--
47,187
56,744
47,264
Changes In Accounts Receivables
--
(16,367)
(26,650)
(8,756)
Changes In Assets and Liabilities
--
46,332
(30,340)
(23,084)
Changes In Inventories
--
(50,989)
(36,847)
(33,910)
Changes In Other Operating Activities
630,210
(76,053)
97,523
135,205
Total Cash Flow From Operating Activities
--
(221,689)
(73,539)
(59,634)
Investing Activities, Cash Flows Provided By or Used In
Capital Expenditures
(96,806)
(227,653)
(118,834)
(65,124)
Investments
--
(451,797)
247,889
(107,284)
Other Cash flows from Investing Activities
96,806
(500,148)
65,500
(126,375)
Total Cash Flows From Investing Activities
--
(1,179,598)
194,555
(298,783)
Financing Activities, Cash Flows Provided By or Used In
Dividends Paid
--
--
--
--
Sale/Purchase of Stock
--
888,257
117,464
0
Net Borrowings
--
--
0
712,630
Other Cash Flows from Financing Activities
--
39,656
68,225
34,041
Total Cash Flows From Financing Activities
--
927,913
185,689
746,671
Effect Of Exchange Rate Changes
--
(5,072)
(3,398)
(2,230)
Change In Cash and Cash Equivalents
--
(478,446)
306,705
388,254

BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information